AUROPHARMA
Aurobindo Pharma
Aurobindo Pharma (AUROPHARMA) Stock Analysis & Case Study
Is AUROPHARMA a good buy? The data-driven verdict.
Aurobindo Pharma (AUROPHARMA) trades at ₹1,492,on the numbers it mixed signals, a Downstox Snapshot Score of 49/100.
On the numbers, Aurobindo Pharma (AUROPHARMA) mixed signals, a Downstox Snapshot Score of 49/100, weighing fairly valued at 24.4× earnings, ROE of 10.1%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
AUROPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is AUROPHARMA overvalued? AUROPHARMA P/E vs its Pharma
AUROPHARMA's P/E of 24.4× sits below the Pharma peer median of 30.0×, so on earnings it screens cheaper than peers, while its 0.27% dividend yield is below the peer median of 0.51%.
The bull case for AUROPHARMA
- A 24.4× P/E sits in the fair-value band, neither cheap nor stretched.
The bear case & risks
- Return on equity is a soft 10.1%, capital efficiency trails higher-quality peers.
AUROPHARMA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. AUROPHARMA scores 4/9,mixed financial health.
AUROPHARMA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy AUROPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 28.6% | 3.5× |
| Zerodha | 24.4% | 4.1× |
| DhanCHEAPEST | 23.0% | 4.3× |
Compare every broker on the AUROPHARMA MTF page.
AUROPHARMA vs peers,Pharma comparison
About Aurobindo Pharma: sector, index & market-cap context
Aurobindo Pharma (AUROPHARMA) is a mid-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹86,647 Cr. See more Nifty 100 stocks.
How the AUROPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Aurobindo Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AUROPHARMA analysis, FAQs
Is Aurobindo Pharma (AUROPHARMA) a good buy?
On the numbers, Aurobindo Pharma (AUROPHARMA) mixed signals, a Downstox Snapshot Score of 49/100, weighing fairly valued at 24.4× earnings, ROE of 10.1%. This is a data snapshot for research, not investment advice.
Is AUROPHARMA overvalued or undervalued?
AUROPHARMA trades at 24.4× earnings versus a peer median of 30.0×, so it screens cheaper than its Pharma peers.
What is the bull case for AUROPHARMA?
A 24.4× P/E sits in the fair-value band, neither cheap nor stretched.
What are the risks in AUROPHARMA?
Return on equity is a soft 10.1%, capital efficiency trails higher-quality peers.